Prot# EGF114299: A Phase III Trial to Compare the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus an Aromatase Inhibitor (AI) Versus Trastuzumab Plus an AI versus Lapatinib an AI as First-Line Therapy in Postmenopausal Subjects with Hormone Recepto

Project: Research project

Project Details

Effective start/end date9/15/119/15/17


  • GlaxoSmithKline plc (EGF114299)